Takeda to launch once-weekly alendronate in Europe
This article was originally published in Scrip
Executive Summary
Takeda is planning the first launches of Steovess (formerly EX101), a once-a-week formulation of 70mg buffered effervescent alendronate, for the treatment of post-menopausal osteoporosis in the second half of 2012 after the European decentralised procedure was positively concluded for the drug, the company said.